The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi.
diffuse large B-cell lymphoma
early mortality
elderly prognostic index
geriatric assessment
survival
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
09
08
2022
received:
28
06
2022
accepted:
17
09
2022
pubmed:
1
10
2022
medline:
3
2
2023
entrez:
30
9
2022
Statut:
ppublish
Résumé
The Elderly Prognostic Index (EPI) is based on the integration of a simplified geriatric assessment, hemoglobin levels and International Prognostic Index and has been validated to predict overall survival in older patients with diffuse large B-cell lymphoma (DLBCL). In this study, we evaluated the ability of EPI to predict the risk of early mortality. This study included all patients registered in the Elderly Project for whom treatment details and a minimum follow-up of 3 months were available. Three main treatment groups were identified based on the anthracycline amount administered: cases receiving >70% of the theoretical anthracyclines dose (Full Dose [FD] group), ≤70% (Reduced Dose [RD]) and palliative therapy (PT; no anthracyclines). The primary endpoint was early mortality rate, defined as death for any cause occurring within 90 days from diagnosis. We identified 1150 patients with a median age of 76 years (range 65-94). Overall, 69 early deaths were observed, accounting for 19% of all reported deaths. The cumulative rate of early mortality at 90 days was 6.0%. Comparing early with delayed deaths, we observed a lower frequency of deaths due to lymphoma progression (42% vs. 75%; p < 0.001) and a higher frequency due to toxicity and infections (22% vs. 4%, p < 0.001, and 22% vs. 3%, p < 0.001, respectively) for early events. A multivariable logistic analysis on 931 patients (excluding PT) confirmed an independent association of high-risk EPI (odds ratio [OR] 3.60; 95% confidence interval [CI] 1.15-11.2) and bulky disease (OR 2.08; 95% CI 1.09-3.97) with the risk of early mortality. The cumulative incidence of early mortality for older patients with DLBCL is not negligible and is mainly associated with non-lymphoma related events. For patients receiving anthracyclines, high-risk EPI and bulky disease are associated with a higher probability of early mortality.
Substances chimiques
Rituximab
4F4X42SYQ6
Antibiotics, Antineoplastic
0
Anthracyclines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
78-87Subventions
Organisme : GRADE Onlus
Organisme : Unicredit Bank
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842-858. https://doi.org/10.1056/NEJMra2027612
Pfreundschuh M, Kuhnt E, Trümper L, et al. MabThera International Trial (MInT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013-1022. https://doi.org/10.1016/S1470-2045(11)70235-2
Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040-2045. https://doi.org/10.1182/blood-2010-03-276246
Khan Y, Brem EA. Considerations for the treatment of diffuse large B cell lymphoma in the elderly. Curr Hematol Malig Rep. 2019;14(4):228-238. https://doi.org/10.1007/s11899-019-00519-7
Kumar A, Fraz MA, Usman M, et al. Treating diffuse large B cell lymphoma in the very old or frail patients. Curr Treat Options Oncol. 2018;19(10):50. https://doi.org/10.1007/s11864-018-0565-6
Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373-2380. https://doi.org/10.1200/JCO.2009.26.2493
Lin RJ, Behera M, Diefenbach CS, Flowers CR. Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. Blood. 2017;130(20):2180-2185. https://doi.org/10.1182/blood-2017-05-736975
Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR, Skettino S. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist. 2014;19(12):1249-1257. https://doi.org/10.1634/theoncologist.2014-0113
Williams JN, Rai A, Lipscomb J, Koff JL, Nastoupil LJ, Flowers CR. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer. 2015;121(11):1800-1808. https://doi.org/10.1002/cncr.29290
Fabbri A, Cencini E, Bocchia M. Treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma. Cancer. 2015;121(20):3746-3747. https://doi.org/10.1002/cncr.29509
Boslooper K, Kibbelaar R, Storm H, et al. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Leuk Lymphoma. 2014;55(3):526-532. https://doi.org/10.3109/10428194.2013.810737
Hamaker ME, Stauder R, van Munster BC. On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points? Ann Oncol. 2014;25(3):675-681. https://doi.org/10.1093/annonc/mdt592
Merli F, Luminari S, Rossi G, et al. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leuk Lymphoma. 2012;53(4):581-588. https://doi.org/10.3109/10428194.2011.621565
Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326-2347. https://doi.org/10.1200/JCO.2018.78.8687
Sedrak MS, Freedman RA, Cohen HJ, et al. Cancer and Aging Research Group (CARG). Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J Clin. 2021;71(1):78-92. https://doi.org/10.3322/caac.21638
Tucci A, Martelli M, Rigacci L, et al. Italian Lymphoma Foundation (FIL). Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma. 2015;56(4):921-926. https://doi.org/10.3109/10428194.2014.953142
Merli F, Luminari S, Tucci A, et al. Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi. J Clin Oncol. 2021;39(11):1214-1222. https://doi.org/10.1200/JCO.20.02465
Peyrade F, Jardin F, Thieblemont C, et al. Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460-468. https://doi.org/10.1016/S1470-2045(11)70069-9
Zettl F, Ziepert M, Altmann B, et al. Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma-data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group). Ann Hematol. 2021;100(4):1031-1038. https://doi.org/10.1007/s00277-020-04345-3
Olszewski AJ, Mantripragada KC, Castillo JJ. Risk factors for early death after rituximab-based immunochemotherapy in older patients with diffuse large B-cell lymphoma. J Natl Compr Cancer Netw. 2016;14(9):1121-1129. https://doi.org/10.6004/jnccn.2016.0121
Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol. 2010;89(9):897-904. https://doi.org/10.1007/s00277-010-0956-7
Royston P, Parmar MKB. Flexible proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15):2175-2197. https://doi.org/10.1002/sim.1203
Susanibar-Adaniya S, Barta SK. Update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617-629. https://doi.org/10.1002/ajh.26151
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994. https://doi.org/10.1056/NEJM199309303291402
Sehn LH, Berry B, Chhanabhai M, et al. The Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861. https://doi.org/10.1182/blood-2006-08-038257
Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837-842. https://doi.org/10.1182/blood-2013-09-524108
Paul U, Richter J, Stuhlmann-Laiesz C, et al. Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC. Leuk Lymphoma. 2018;59(5):1213-1221. https://doi.org/10.1080/10428194.2017
Klapper W, Kreuz M, Kohler CW, et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood. 2012;119(8):1882-1887. https://doi.org/10.1182/blood-2011-10-388470
Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-3127. https://doi.org/10.1200/JCO.2005.05.1003
Pfreundschuh M, Schubert J, Ziepert M, et al. German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105-116. https://doi.org/10.1016/S1470-2045(08)70002-0
Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer. 2009;115(19):4547-4553. https://doi.org/10.1002/cncr.24490
Ong DM, Ashby M, Grigg A, et al. Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations. Br J Haematol. 2019;187(1):73-81. https://doi.org/10.1111/bjh.16049
Merli F, Luminari S, Rossi G, et al. Fondazione Italiana Linfomi. Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by comprehensive geriatric assessment: results from a study of the Fondazione Italiana Linfomi. Leuk Lymphoma. 2014;55(1):38-43. https://doi.org/10.3109/10428194.2013.788176
Yoshida M, Nakao T, Horiuchi M, et al. Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for ‘unfit’ patients classified by comprehensive geriatric assessment. Eur J Haematol. 2016;96(4):409-416. https://doi.org/10.1111/ejh.12608
Spina M, Balzarotti M, Uziel L, et al. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist. 2012;17(6):838-846. https://doi.org/10.1634/theoncologist.2011-0417
Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011;29(10):1290-1296. https://doi.org/10.1200/JCO.2010.30.6985
Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer. 2012;118(13):3377-3386. https://doi.org/10.1002/cncr.26646
Dhir V, Maganti M, Rozenberg D, et al. Predicting the risks of aggressive-intent chemotherapy toxicity in older patients with lymphoma: a prospective observational pilot study. Clin Lymphoma, Myeloma & Leukemia. 2022;22(8):792-803. https://doi.org/10.1016/j.clml.2022.04.011
Cho SF, Liu YC, Hsiao HH, et al. Investigation on treatment strategy, prognostic factors, and risk factors for early death in elderly Taiwanese patients with diffuse large B-cell lymphoma. Sci Rep. 2017;7(1):44282. https://doi.org/10.1038/srep44282
Smith TJ, Bohlke K, Lyman GH, Carson KR, American Society of Clinical Oncology. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199-3212. https://doi.org/10.1200/JCO.2015.62.3488
Pfreundschuh M, Trümper L, Kloess M, et al. German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634-641. https://doi.org/10.1182/blood-2003-06-2095
Lin RJ, Owens CN, Drill E, et al. Prephase rituximab/prednisone therapy and aging-related, pro-inflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma. Haematologica. 2021. Online ahead of print. https://doi.org/10.3324/haematol.2021.278719
Hohaus S, Tisi MC, Bellesi S, et al. Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. Cancer Med. 2018;7(1):270-281. https://doi.org/10.1002/cam4.1166